UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G
Under the Securities Exchange Act of 1934

Akoya Biosciences, Inc.
(Name of Issuer)
 
Common Stock, Par Value $0.00001 per Share
(Title of Class of Securities)
 
 00974H104
(CUSIP Number)

June 12, 2023
(Date of Event which Requires Filing of this Statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
☐ Rule 13d-1(b)
 
☒ Rule 13d-1(c)
 
☐ Rule 13d-1(d)
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
 

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
aMoon Growth Fund II, L.P.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Cayman Islands 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
2,500,000
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
2,500,000
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
2,500,000
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
5.16%(1)
12.
Type of Reporting Person (See Instructions)
 
PN 

(1)
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

Page 2 of 19 Pages

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
aMoon Growth Fund II G.P., L.P.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
2,500,000
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
2,500,000
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
2,500,000
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
5.16%(1)
12.
Type of Reporting Person (See Instructions)
 
PN 

(1)
(Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
 
Page 3 of 19 Pages


CUSIP No.
00974H104
1.
Names of Reporting Persons
 
aMoon Growth II General Partner Ltd.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
2,500,000
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
2,500,000
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
2,500,000
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
5.16%(1)
12.
Type of Reporting Person (See Instructions)
 
CO
 
(1)
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

Page 4 of 19 Pages

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
aMoon Edge Limited Partnership
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
418,439
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
418,439
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
418,439
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
0.86% (1)
12.
Type of Reporting Person (See Instructions)
 
PN

(1)
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

Page 5 of 19 Pages
 
CUSIP No.
00974H104
1.
Names of Reporting Persons
 
aMoon Edge GP Ltd.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
418,439
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
418,439
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
418,439
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
0.86% (1)
12.
Type of Reporting Person (See Instructions)
 
CO

(1)
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

Page 6 of 19 Pages

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
Hilliyon Holdings Ltd.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
418,439
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
418,439
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
418,439
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
0.86% (1)
12.
Type of Reporting Person (See Instructions)
 
CO

(1)
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

Page 7 of 19 Pages

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
Berko Capital Ltd.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
418,439
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
418,439
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
418,439
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
0.86% (1)
12.
Type of Reporting Person (See Instructions)
 
CO

(1)
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

Page 8 of 19 Pages

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
Dr. Yair C. Schindel
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
2,918,439
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
2,918,439
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
2,918,439
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
6.03% (1)
12.
Type of Reporting Person (See Instructions)
 
IN

(1)
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

Page 9 of 19 Pages
 
CUSIP No.
00974H104
1.
Names of Reporting Persons
 
Dr. Tomer Berkovitz
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
418,439
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
418,439
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
418,439
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
0.86% (1)
12.
Type of Reporting Person (See Instructions)
 
IN

(1)
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

Page 10 of 19 Pages

Item 1(a)            Name of Issuer
 
Akoya Biosciences, Inc. (the “Issuer”).
 
Item 1(b)            Address of Issuer’s Principal Executive Offices
 

100 Campus Drive, 6th Floor, Marlborough, MA 01752.
 
Item 2(a)-(b)      Name of Person Filing; Address of Principal Business Office or, if none, Residence
 

 1.
aMoon Growth Fund II, L.P. (“aMoon”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 2.
aMoon Growth Fund II G.P., L.P. (“aMoon G.P.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 3.
aMoon Growth II General Partner Ltd., (“aMoon Ltd.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 4.
aMoon Edge Limited Partnership (“aMoon Edge”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 5.
aMoon Edge GP Ltd., (“aMoon Edge Ltd.”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 6.
Hilliyon Holdings Ltd., (“Hilliyon”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 7.
Berko Capital Ltd., an Israeli company (“Berko Capital”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 8.
Dr. Yair C. Schindel (“Schindel”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 9.
Dr. Tomer Berkovitz (“Berkovitz”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”.

Item 2(c)            Citizenship
 

aMoon is a Cayman Islands exempted limited partnership; aMoon G.P. is a Cayman Islands exempted limited partnership; aMoon Ltd. is an Israeli company; aMoon Edge is a Cayman Islands exempted limited partnership; aMoon Edge Ltd. is a Cayman Islands company; Hilliyon is an Israeli company; Berko Capital is an Israeli company; Schindel is an Israeli citizen and Berkovitz is an Israeli citizen.
 
Page 11 of 19 Pages
Item 2(d)            Title of Class of Securities
 

Common Stock, par value $0.00001 per share

Item 2(e)            CUSIP Number
 

00974H104
 
Item 3
If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
 

Not applicable.
 
Item 4                 Ownership
 
All share percentage calculation below are based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

aMoon Growth Fund II, L.P.
 

 (a)
Amount beneficially owned:  2,500,000 shares of Common Stock.


(b)
Percent of Class: 5.16%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 2,500,000 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 2,500,000 shares of Common Stock
 
aMoon Growth Fund II G.P., L.P.
 

 (a)
Amount beneficially owned:  2,500,000 shares of Common Stock.


(b)
Percent of Class: 5.16%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 2,500,000 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 2,500,000 shares of Common Stock.
Page 12 of 19 Pages
 

aMoon Growth II General Partner Ltd.
 

 (a)
Amount beneficially owned:  2,500,000 shares of Common Stock.


(b)
Percent of Class: 5.16%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 2,500,000 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 2,500,000 shares of Common Stock.
 

aMoon Edge Limited Partnership
 

 (a)
Amount beneficially owned:  418,439 shares of Common Stock.


(b)
Percent of Class: 0.86%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 418,439 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock.


aMoon Edge GP Ltd.


(a)
Amount beneficially owned:  418,439 shares of Common Stock.


(b)
Percent of Class: 0.86%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 418,439 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock.
 

Hilliyon Holdings Ltd.


(a)
Amount beneficially owned:  418,439 shares of Common Stock.


(b)
Percent of Class: 0.86%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 418,439 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock.

Page 13 of 19 Pages
Berko Capital Ltd.


(a)
Amount beneficially owned:  418,439 shares of Common Stock.


(b)
Percent of Class: 0.86%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 418,439 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0


(iv)
Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock.


Dr. Yair C. Schindel


(a)
Amount beneficially owned: 2,918,439 shares of Common Stock.  (i) Schindel is the sole shareholder of aMoon Ltd. By virtue of such relationships, Schindel may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon; (ii) aMoon Edge Ltd. is the sole general partner of aMoon Edge pursuant to the terms of the limited partnership agreement of aMoon Edge.  Hilliyon and Berko Capital are the sole shareholders of aMoon Edge Ltd. and Schindel is the sole shareholder of Hilliyon. By virtue of such relationships, Schindel may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon Edge. Schindel disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon, aMoon G.P. aMoon Ltd., aMoon Edge, aMoon Edge Ltd., and Hilliyon, except to the extent of his pecuniary interest therein, if any.


(b)
Percent of Class: 6.03%


(c)
Number of shares as to which the  person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 2,918,439  shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 2,918,439 shares of Common Stock.
 
Dr. Tomer Berkovitz


(a)
Amount beneficially owned: 418,439 shares of Common Stock.  Hilliyon and Berko Capital are the sole shareholders of aMoon Edge Ltd., and Berkovitz is the sole shareholder of Berko Capital. By virtue of such relationships, Berkovitz may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon Edge. Berkovitz disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon Edge, aMoon Edge Ltd. and Berko Capital, except to the extent of his pecuniary interest therein, if any.


(b)
Percent of Class: 0.86%


(c)
Number of shares as to which the  person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 418,439  shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock
 
Item 5
Ownership of Five Percent or Less of a Class


Not applicable.

Item 6
Ownership of More than Five Percent on Behalf of Another Person


Not applicable.

Item 7
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
 

Not applicable.

Page 14 of 19 Pages
 
Item 8
Identification and Classification of Members of the Group
 

Incorporated by reference to Items 2 and 4 of this Schedule 13G.
 
Item 9
Notice of Dissolution of Group
 

Not applicable.

Item 10
Certification
 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 15 of 19 Pages
Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
Dated: June 13, 2023

AMOON GROWTH FUND II L.P.
BY: AMOON GROWTH FUND II G.P., L.P., ITS GENERAL PARTNER
BY:  AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER
By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
AMOON GROWTH FUND II G.P., L.P.,
BY:  AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER

By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director

AMOON GROWTH II GENERAL PARTNER LTD.
 
By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
AMOON EDGE LIMITED PARTNERSHIP
BY:  AMOON EDGE GP LTD., ITS GENERAL PARTNER
 
By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
Page 16 of 19 Pages

AMOON EDGE GP LTD.
 
By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director

HILLIYON HOLDINGS LTD.
 
By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director

BERKO CAPITAL LTD.
 
By:
/s/ Dr. Tomer Berkovitz
 
Name:
Title:
Dr. Tomer Berkovitz
Director

DR. YAIR C. SCHINDEL
/s/ Dr. Yair C. Schindel
  

DR. TOMER BERKOVITZ
 
/s/ Dr. Tomer Berkovitz
  

Page 17 of 19 Pages

EXHIBIT A TO SCHEDULE 13G

Joint Filing Agreement

The undersigned hereby agree that the Schedule 13G (the “Schedule 13G”), filed by the undersigned with respect to shares of Common Stock, par value $0.00001 per share, of Akoya Biosciences, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Joint Filing Agreement (this “Agreement”) shall be included as an Exhibit to the Schedule 13G.  Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein.  This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.  

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement this 13th day of June 2023.
 
 
AMOON GROWTH FUND II L.P.
BY: AMOON GROWTH FUND II G.P., L.P., ITS GENERAL PARTNER
BY:  AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
 
AMOON GROWTH FUND II G.P., L.P.,
BY:  AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER
 
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director

 
AMOON GROWTH II GENERAL PARTNER LTD.
 
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
 
AMOON EDGE LIMITED PARTNERSHIP
BY:  AMOON EDGE GP LTD., ITS GENERAL PARTNER
 
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
Page 18 of 19 Pages

 
AMOON EDGE GP LTD.
 
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director

 
HILLIYON HOLDINGS LTD.
 
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director

 
BERKO CAPITAL LTD.
 
 
By:
/s/ Dr. Tomer Berkovitz
 
 
Name:
Title:
Dr. Tomer Berkovitz
Director

 
DR. YAIR C. SCHINDEL
 
/s/ Dr. Yair C. Schindel

 
DR. TOMER BERKOVITZ
 
 
/s/ Dr. Tomer Berkovitz

Page 19 of 19 Pages
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Akoya BioSciences Charts.
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Akoya BioSciences Charts.